“This is a breakthrough in the revolutionary era of precision therapy. The ability to determine the patient’s level of PD-L1 expression is critical to providing novel therapy options in a targeted and cost-effective manner,” said CGI president and CEO, Panna Sharma.
Roberts Brings Track Record of Value-Creation & Disciplined Growth In Healthcare Technology and Service Companies. Roberts Will Fill Newly Formed Positions of Chief Operating Officer and Executive Vice President of Finance Based in New Jersey
TOO® is the ONLY FDA-cleared test of its type, used to aid in identifying challenging tumors, including metastatic, poorly differentiated, and undifferentiated cancers The partnership will leverage Sayre’s distribution and sales personnel that engages over 500 key opinion and healthcare business leaders vital in the Indian oncology landscape Rutherford, N.J., USA and Hyderabad, India, June […]
RUTHERFORD, N.J., June 07, 2016 — Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that Panna Sharma, President and CEO, will present a corporate overview at LD Micro’s Sixth Invitational Conference on Wednesday, June 8, 2016 at 11:00 AM Pacific […]
TUCSON, Ariz. and LOS ANGELES, Calif. June 6, 2016 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM; “HTG”), a provider of instruments and reagents for molecular profiling applications, and Cancer Genetics, Inc. (Nasdaq: CGIX; “CGI”), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced the acceptance of a […]
Boulder, CO, June 3, 2016 – ArcherDX, Inc., a leader in NGS-based gene fusion detection, has announced that Cancer Genetics, Inc., (CGI) has become a Certified Service Provider of Archer® FusionPlex® NGS assays. Additionally, CGI plans to use Archer VariantPlexTM assays to identify copy number variants (CNVs) and point mutations in tumor samples and will be testing […]
Rutherford, NJ, May 20, 2016 – Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics” or the “Company”), an emerging leader in DNA-based cancer diagnostics, today announced that it has entered into definitive agreements with healthcare focused institutional investors for an offering of 2.5 million shares of common stock with gross proceeds of approximately $5 million in […]
The panel provides Critical Genomic Information To Improve Patient Management & Guide Therapy Decisions FOCUS::Lymphoma™ panel is being used to power several clinical trials with biotech and pharmaceutical companies, and is now available for use in a clinical setting FOCUS::Lymphoma™ can be personalized to report on clinically actionable gene mutations present in the most common types […]
Company reports record quarterly revenues of $6.1 million, an increase of 39% over Q1 2015 and 11% over Q4 2015 Significant expansion of new Immuno-Oncology (IO) test offering, with expansion into 12 active IO focused clinical trials with leading global companies Signed contracts for expected future revenues with biotech and pharma companies increases to over […]
Rutherford, NJ – May 5, 2016 – Cancer Genetics, Inc. (CGIX) (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that Panna Sharma, President and CEO, will present a corporate overview at the Pioneers 2016 Conference presented by Joseph Gunnar & Co., LLC on Thursday, May 5, […]
CGI is uniquely positioned to deliver comprehensive immune marker and genomic data in oncology for biopharma partners and clinical centers for both solid and blood cancers CGI is also actively involved in 3 academic collaborations discovering and validating responder and non-responder patient groups for immuno-oncology drugs in melanoma, lung cancer and lymphoma Rutherford, NJ & […]
RUTHERFORD, NJ – May 3, 2016 – Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that it will report financial results for the first quarter ended March 31, 2016 after the market close on Tuesday, May 10, 2016. The company will also hold […]
Full-Year 2015 revenues up 77% year-over-year to $18 Million Fourth Quarter revenues up 36% year-over-year to $5.5 Million Closed 2015 with strong cash balance of $19.5 Million Conference call begins at 5:00 p.m. Eastern time today RUTHERFORD, N.J., March 10, 2016 — Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in enabling precision medicine for oncology […]
“…we have been working closely with several clinical and biopharma customers to uniquely refine this powerful test … As a result, we have several customers that have ensured that we launch this NGS panel to meet market demands and generate revenue immediately.” said Panna Sharma, Chief Executive Officer and President of CGI.
RUTHERFORD, NJ – March 3, 2016 – Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that it will report financial results for the fourth quarter and fiscal year ended December 31, 2015 after the market close on Thursday, March 10, 2016. The company […]
President and CEO Panna Sharma is scheduled to present a corporate overview and participate in an industry roundtable conference at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference.
“CGI is thrilled to work with Blue Cross Blue Shield of Minnesota,” said Randy Goodman, Ph.D., Director of Reimbursement and Clinical Revenue Cycle Management at Cancer Genetics, Inc.
Immuno-oncology drugs are expected to reach $35 billion in sales by 2024 and potentially impact up to 60% of all cancer patients Cancer Genetics, Inc. will offer immuno-oncology marker testing and technologies for both solid tumors and blood based cancers Rutherford, NJ & Los Angeles, CA, Thursday January 21, 2016 – Cancer Genetics, Inc. (Nasdaq: […]
Study Results Provide Actionable Information to Develop Customized Treatment of Renal Cell and Metastatic ccRCC Patients RUTHERFORD, N.J., January 06, 2016 — Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), an emerging leader in DNA-based cancer diagnostics announced the presentation of results from collaborative studies with Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College. […]
TRENTON (December 22, 2015) – When it comes to treating cancer, early detection and a personalized treatment plan can be critical. Rutherford-based Cancer Genetics, Inc. (CGI) is a key player in the development of tools that help physicians and pharmaceutical companies identify genomic markers to determine the best and most efficient cancer treatments. CGI’s “bench to […]